20th Nov 2015 07:26
LONDON (Alliance News) - AstraZeneca PLC on Friday said it has directly exchanged 210,000 chemical compounds with French pharmaceutical company Sanofi SA from their respective compound libraries.
The company said the swap "enhances the chemical diversity of the compound collections of both companies and allows each to screen a broader, more diverse chemical space as the starting point in the search for new small-molecule medicines."
The compounds have been selected based on differences to those in their own libraries. There are no payments involved in the compound exchange.
"This is a highly innovative agreement which speaks to our open innovation approach. We've worked hard to enrich our compound library in recent years and this exchange, which is by far the largest we have achieved, enables us to significantly increase its diversity. Most importantly, it will accelerate our ability to identify unique starting points that could become new medicines for patients," said Mene Pangalos, executive vice president of innovative medicines and early development at AstraZeneca in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca